If you have been reading about circadian rhythm and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
The statue of Augustus of Prima Porta was discovered within the Villa of Livia in 1863. Little is known about the discovery itself and its immediate aftermath, as the incomplete archaeological journals leave ambiguous evidence for modern historians. The statue was first publicized by the German archaeologist Wilhelm Henzen in 1863 in the Bulletino dell'Instituto di Corrispondenza Archaeologica. The exact location of the statue within the villa is unknown. Suggested sites are the underground complex, a placement near a staircase, the villa's atrium, or in a laurel grove on the southeast corner of Prima Porta hill. Scholars have stated that the last one is relatively unconvincing compared with the first three. The theory that Augustus's statue was found in the underground complex of the villa is based on a hypothesis that Augustus holds a laurel branch instead of a spear in his left hand. Scholars have noted that if this hypothesis is correct, then Villa of Livia must have been decorated with laurel groves and that the reason of the decoration is the omen of the gallina alba (Latin: white hen). Recent excavations have discovered the remnants of pots used to plant laurel on the edge of the Prima Porta hill in front of the underground complex, which Reeder believes suggests the possibility of the existence of laurel groves in the villa and makes it likely that the statue was located in the underground complex.
In classical homocystinuria (CBS, or cystathione beta synthase deficiency), the plasma methionine level usually increases above the normal range of 30 micromoles/L and the concentrations should be monitored as potentially toxic levels (more than 400 micromoles/L) may be reached.
During the bidding process, 41 cities with 42 existing, fully functional venues with regular tenants (except Olympic Stadium in Montreal) and two venues then under construction (Allegiant Stadium in Las Vegas and SoFi Stadium in Los Angeles) submitted to be part of the bid: three venues in three cities in Mexico, six venues in six cities in Canada, and 35 venues in 32 cities in the United States. A first-round elimination removed nine venues and nine cities. A second-round elimination cut an additional nine venues in six cities, while three venues in three cities (Soldier Field in Chicago, U.S. Bank Stadium in Minneapolis, and BC Place in Vancouver) dropped out because FIFA was unwilling to negotiate financial details. After Montreal dropped out in July 2021 because it lacked provincial funding and support to renovate Olympic Stadium, Vancouver rejoined the bid as a candidate city in April 2022, bringing the total number to 24 venues, each in its own city or metropolitan area. On June 16, 2022, the sixteen host cities–two in Canada, three in Mexico, and eleven in the United States–were announced by FIFA: Atlanta, Boston, Dallas, Guadalajara, Houston, Kansas City, Los Angeles, Mexico City, Miami, Monterrey, New York/New Jersey, Philadelphia, San Francisco Bay Area, Seattle, Toronto, and Vancouver. Eight of the sixteen chosen stadiums had permanent artificial turf surfaces that were replaced with grass under the direction of FIFA and a University of Tennessee–Michigan State University research team.
These observations did not demonstrate whether cholesterol present in the animal body was due to synthesis or whether it had all actually come from vegetable food. The transformation of plant sterols into cholesterol within the body of an animal requires the sterol to be absorbable. This is the notion Schoenheimer investigated in his experiments. One of his experiments involved administering two different diets to a group of rabbits. Rabbits are sensitive to a diet which includes cholesterol, and their bodily responses particularly that of the aorta demonstrates a change that similarly resembles the Human atherosclerosis. In the experiment one diet involved a large amount of sito-sterol, which is a type of plant sterol. The other diet included cholesterol. The observations of the experiment indicated that Schoenheimer and his associates' theories that plant sterols were not absorbable were probable. Furthur studies were conducted and the findings concluded that plant sterols were non-absorbable, and therefore animals with plant only diets must synthesise the cholesterol necessary for their tissues as they do not receive absorbable cholesterol. During this period Schoenheimer became aware that cholesterol had an intermediary metabolism and that it was chemically inconvertable with other sterols. In one of his later experiments using sterols, he did discover a small percentage of one sterol, dihydrocholesterol in animal tissue. He investigated this finding using a dog which showed dihydrocholesterol was formed in the tissues.
Sources: en.wikipedia.org
Endomorphins are natural, endogenous opioid neuropeptides that are considered to be central to pain relief. They were first described in 1997 by James Zadina, Abba Kastin and colleagues. The two known endomorphins, endomorphin-1 and endomorphin-2, are tetrapeptides, consisting of Tyr-Pro-Trp-Phe and Tyr-Pro-Phe-Phe amino acid sequences respectively. These sequences fold into tertiary structures with high specificity and affinity for the μ-opioid receptor, binding it exclusively and strongly. Bound μ-opioid receptors typically induce inhibitory effects on neuronal activity. Endomorphin-like immunoreactivity exists within the central and peripheral nervous systems, where endomorphin-1 appears to be concentrated in the brain and upper brainstem, and endomorphin-2 is located mainly in the spinal cord and lower brainstem. Because endomorphins activate the μ-opioid receptor, which is the target receptor of morphine and its derivatives, endomorphins possess significant potential as analgesics with reduced side effects and risk of addiction.
=== COVID 19 === The COVID 19 pandemic marked a new chapter in Hetero’s public health contributions. In March 2020, as the pandemic took hold, Hetero donated INR 10 crore to the Telangana government’s COVID relief fund, composed of 5 crores in direct funding and 5 crores in essential medicines including Hydroxychloroquine Sulphate, Lopinavir/Ritonavir and Oseltamivir. During this period, Hetero also began supplying medicines to countries such as the United States, Italy, Spain, Israel, and Algeria. In May 2020, Hetero entered a licensing agreement with Gilead Sciences to manufacture and distribute a generic version of Remdesivir in 127 countries. The Drug Controller General of India granted manufacturing and marketing approval on 21 June 2020, making Covifor the first generic Remdesivir approved in India. An initial consignment of 20000 Vials was distributed within India across major cities including Hyderabad, Delhi, Mumbai, Kolkata and Chennai, priced at ₹5400 per vial. By August 2020, Hetero had supplied approximately 800000 doses of Remdesivir in India alone, treating more than 100000 patients. In the same month, Hetero received authorization from the South African Health Products Regulatory Authority (SAHPRA) to import 'Remdesivir' in South Africa for the treatment for Covid-19, and committed to supplying 60000 vials a month. In July 2020, Hetero received approval from the DCGI to manufacture and market a generic version of Favipiravir tablets under the name Favivir, which is used to treat patients with mild to moderate COVID-19 symptoms.
Chemical energy (or "chemical fuels") was an attractive option at the beginning, given the broad array of reversible chemical reactions (heavily based on acid-base chemistry) to switch molecules between different states. However, this comes with the issue of practically regulating the delivery of the chemical fuel and the removal of waste generated to maintain the efficiency of the machine as in biological systems. Though some AMMs have found ways to circumvent this, more recently waste-free reactions such based on electron transfers or isomerization have gained attention (such as redox-responsive viologens). Eventually, several different forms of energy (electric, magnetic, optical and so on) have become the primary energy sources used to power AMMs, even producing autonomous systems such as light-driven motors.
=== tif-tik === tifacogin (INN) tifemoxone (INN) tifenamil (INN) tifencillin (INN) tiflamizole (INN) tiflorex (INN) tifluadom (INN) tiflucarbine (INN) tiformin (INN) tifurac (INN) tifuvirtide (INN) Tigan tigapotide (USAN) tigatuzumab (USAN) tigecycline (USAN) tigemonam (INN) tigestol (INN) tigloidine (INN) Tiject-20 Tikosyn
== Biosynthesis == The biosynthesis of colistin requires the use of three amino acids: threonine, leucine, and 2,4-diaminobutyric acid. The linear form of colistin is synthesized before cyclization. Non-ribosomal peptide biosynthesis begins with a loading module and then the addition of each subsequent amino acid. The subsequent amino acids are added with the help of an adenylation domain (A), a peptidyl carrier protein domain (PCP), an epimerization domain (E), and a condensation domain (C). Cyclization is accomplished by a thioesterase. The first step is to have a loading domain, 6-methylheptanoic acid, associate with the A and PCP domains. Now with a C, A, and PCP domain that is associated with 2,4-diaminobutyric acid. This continues with each amino acid until the linear peptide chain is completed. The last module will have a thioesterase to complete the cyclization and form the product colistin.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.